Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Late-Stage Obesity Pipeline Is Stuffed With Mix Of Mechanisms

This article was originally published in Pharmaceutical Approvals Monthly

  • News

Following the rejection of three late-stage obesity candidates, there is uncertainty for drugs remaining in the pipeline. In particular, regulatory scrutiny is expected to be intense for drugs that have potential for cardiovascular and/or psychiatric effects. Sources: Inteleos, company websites.

Drug name/Sponsor

Mechanism of action

NDA Submitted, Received “Complete Response” Letter From FDA

Qnexa (phentermine/topiramate)/Vivus

Appetite suppressant/anticonvulsant

Contrave (buproprion SR/naltrexone SR)/Orexigen and Takeda

Proprietary combination formulation of approved antidepressant and approved opioid inhibitor

Lorcaserin/Arena and Eisai

Selective serotonin 2C receptor antagonist

Phase III

Victoza (liraglutide)/Novo Nordisk

Glucagon-like peptide 1 analog approved for diabetes

Cetilistat/Takeda (Norgine holds rights)

Lipase inhibitor

Phase II

Empatic (zonisamide/buproprion SR)/Orexigen

Proprietary combination of zonisamide, a sulfonamide anticonvulsant approved for epilepsy, and buproprion

BMS830216/Bristol-Myers Squibb

Melonin concentrating hormone receptor 1 antagonist

Canagliflozin/Johnson & Johnson and Mitsubishi Tanabe Pharma

Sodium glucose co-transporter 2 inhibitor, also being tested in diabetes

GSK1521498/GlaxoSmithKline

Mu-opioid inverse receptor antagonist

Velneperit (S-2367)/Shionogi

Neuropeptide Y receptor Y5 antagonist

Tesofensine/NeuroSearch

Acetylcholine release enhancer; noradrenaline reuptake inhibitor; dopamine reuptake inhibitor; serotonin reuptake inhibitor

TTP-435/Transtech

Selective inhibitor of agouti related protein

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS004714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By